您的瀏覽器並不支援JavaScript,但影響頁面呈現,您仍可瀏覽本網頁!
ACADEMIA SINICA INSTITUTE OF BIOMEDICAL SCIENCES
中文 | home | sitemap | contact背景圖
背景圖 conferences research divisions graduate programs research highlight 背景圖
seminars awards&news job opportunities research resources
  introduction core facilities funding opportunities  

:::

research divisions
____________________

 

 

Epidemiology & Genetics
Joint
Cross Div.
Cardiovascular Disease
Joint
Cross Div.

 

Cell & Developmental Biology/Regenerative Medicine
Joint
Cross Div.
Structural Biology

 

Infectious Disease &
Immunology
Cross Div.

 

Cancer
Joint
Corresponding
Cross Div.
Neuroscience
Corresponding
Cross Div.
Research Scientist
Adjunct / Emeritus
Research Divisions information
Jou, Yuh-Shan's picture

Jou, Yuh-Shan

Research Fellow and Deputy Director

 

Specialty:

  1. Cancer Genomics
  2. Molecular Cancer Biology
  3. Bioinformatics

Ph.D., Michigan State University

TEL:   27899062,26523525(Lab);26523521(O)

FAX:   27827654

E-mail:   jou@ibms.sinica.edu.tw

PubMed | Recent Publication

Research Description

    My laboratory is interesting in finding novel target genes of prevalent cancers in Taiwan for clinical applications. We apply cutting-edge approaches such as genomics, bioinformatics, epigenomics and molecular cell biology to dissect tumorigenic pathways, study molecular mechanisms of tumor progression and develop therapeutic strategies. We recently established a protocol to analyze copy number alterations (CNA) in cancer genomes using high density SNP arrays with non-paired reference genomes and identify two common altered target genes in human hepatocellular carcinoma (HCC). The protocol further allows us to profile genome-wide alterations of more than 520 human cell lines and established a very useful database IGRhCellID for various applications including cell authenticity, selection of cell line with designated genetic background, and detection of common altered loci and genes in cancer genome. Other projects are studies of (1) tumorigenic mechanisms of aberrant cancer genes involved in 13q12.1 homozygous deleted region; (2) low toxic combination cancer therapy targeting epigenetically activated cancer metastasis genes; (3) integrated genomic and bioinformatic approaches for revealing cancer targets for diagnosis and therapy in human HCC and lung cancer; (4) molecular mechanisms of novel somatic mutations involved in tumor pathogenesis; and (5) molecular mechanisms of betel quid chewing induced oral carcinogenesis.


Selected Recent Publication

    1. Wang YW, Lin KT, Chen SC, Gu DL, Chen CF, Du PH, Jou YS*, Overexpressed-EIF3I Interacted and Activated Oncogenic Akt1 is a Theranostic Target in Human Hepatocellular Carcinoma. Hepatology 2013, PMID: 23460382.
    2. Lin KT, Wang YW, Chen CT, Ho CM, Su WH, Jou YS*. HDAC inhibitors augmented cell migration and metastasis through induction of PKCs leading to identification of low toxicity modalities for combination cancer therapy. Clinical Cancer Res. 2012 Sep 1;18(17):4691-701.
    3. Chang CY, Lin SC, Su WH, Ho CM, Jou YS*. Somatic LMCD1 mutations promoted cell migration and tumor metastasis in hepatocellular carcinoma. Oncogene 2012, May 24; 31(21):2640-52.
    4. Kao S, Shiau CK, Gu DL, Ho CM, Su WH, Chen CF, Lin CH, Jou YS*. IGDB.NSCLC: Integrated Genomic Database of Non-Small Cell Lung Cancer, Nucleic Acids Res. 2012 Jan; 40:D972-D977
    5. Wang YW, Tu PH, Lin KT, Lin SC, Ko JY, Jou YS*.Identification of Oncogenic Point Mutations and Hyperphosphorylation of ALK in Lung Cancer. Neoplasia 2011 Aug 13 (8):704-15.
    6. Shiau CK, Gu DL, Chen CF, Lin CH, Jou YS*. IGRhCellID: Integrated Genomic Resources of human Cell Lines for Identification. Nucleic Acids Res. 2011 Jan; 39: D520-D524.
    7. Chen CF, Hsu EC, Lin KT, Tu PH, Chang HW, Lin CH, Chen YJ, Gu DL, Lin CH, Wu JY, Chen YT, Hsu MT, Jou YS*. Overlapping High Resolution Copy Number Alterations in Cancer Genomes Identified Putative Cancer Genes in Hepatocellular Carcinoma. Hepatology 2010 Nov; 52(5): 1690-701. (Article selected as significant research achievement of Academia Sinica 2010)
    8. Jou YS, Lo YL, Hsiao CF, Chang GC, Tsai YH, Su WC, Chen YM, Huang MS, Chen HL, Chen CJ, Yang PC, Hsiung CA. Association of an EGFR Intron 1 SNP with Never-Smoking Female Lung Adenocarcinoma Patients. Lung Cancer. (2009) 64(3):251-6.
    9. Chen JY, Hung CC, Huang KL, Chen YT, Liu SY, Chiang WF, Chen HR, Yen CY, Wu YJ, Ko JY and Jou YS* Src Family Kinases Mediate Betel Quid–Induced Oral Cancer Cell Motility and Could Be a Biomarker for Early Invasion in Oral Squamous Cell Carcinoma.Neoplasia 2008 Dec, 10(12): 1393-1401.
    10. Sen PK*, Tsai MT*, and Jou YS*.High Dimension Low Sample Size Perspectives in Constrained Statistical Inference: The SARSCoV RNA Genome in Illustration.Journal of the American Statistical Association. 2007, Jun, 102 (478): 686-694.
    11. Chang YL, Wu CT, Lin SC, Hsiao CF, Jou YS* and Lee YC*.Clonality and Prognostic Implications of p53 and EGFR Somatic Aberrations in Multiple Primary Lung Cancers.Clinical Cancer Res.2007 Jan 1; 13(1):52-8.
    12. Su WH, Chao CC, Yeh SH, Chen DS, Chen PJ, and Jou YS*.OncoDB.HCC: An Integrated Oncogenomic Database of Hepatocellular Carcinoma Revealed Aberrant Cancer Target Genes and Loci. Nucleic Acids Res. 2007 Jan; 35:D727-31.